APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasma Derived Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Plasma Derived Medicine Market Outlook and Growth Opportunities 2026

31 December 2025205 pages

Choose your research edition.

Industry ResearchPlasma Derived Medicine Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma Derived Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Plasma Derived Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma Derived Medicine Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma Derived Medicine Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Plasma Derived Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Plasma Derived Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Plasma Derived Medicine market include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Plasma Derived Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Plasma Derived Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Plasma Derived Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Plasma Derived Medicine market.

Plasma Derived Medicine Segment by Company

Yuanda Shuyang

Takeda

Weiguang Bio

Tiantan Bio

CBPO

Shuanglin Bio

RAAS

Nanyue Bio

Hualan Bio

Boya Bio

Octapharma

LFB Group

KM Biologics

Kedrion

Grifols

CSL

BPL

Biotest

Plasma Derived Medicine Segment by Type

Albumin

Immune Globulin

Coagulation Factor

Others

Plasma Derived Medicine Segment by Application

Hospital

Retail Pharmacy

Other

Plasma Derived Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Plasma Derived Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Plasma Derived Medicine key companies, revenue, market share, and recent developments.

3. To split the Plasma Derived Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Plasma Derived Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Plasma Derived Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Plasma Derived Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Derived Medicine industry.

Chapter 3: Detailed analysis of Plasma Derived Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Plasma Derived Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Plasma Derived Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Plasma Derived Medicine Industry Trends Table 2. Plasma Derived Medicine Industry Drivers Table 3. Plasma Derived Medicine Industry Opportunities and Challenges Table 4. Plasma Derived Medicine Industry Restraints Table 5. Global Plasma Derived Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Plasma Derived Medicine Revenue Share by Company (2021-2026) Table 7. Global Plasma Derived Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Plasma Derived Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Plasma Derived Medicine Company, Product Type & Application Table 10. Global Plasma Derived Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Plasma Derived Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Albumin Table 15. Significant Companies of Immune Globulin Table 16. Significant Companies of Coagulation Factor Table 17. Significant Companies of Others Table 18. Global Plasma Derived Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Plasma Derived Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Plasma Derived Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Plasma Derived Medicine Sales Value Share by Type (2021-2026) Table 22. Global Plasma Derived Medicine Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Other Table 26. Global Plasma Derived Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Plasma Derived Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Plasma Derived Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Plasma Derived Medicine Sales Value Share by Application (2021-2026) Table 30. Global Plasma Derived Medicine Sales Value Share by Application (2027-2032) Table 31. Global Plasma Derived Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Plasma Derived Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Plasma Derived Medicine Sales Value Share by Region (2021-2026) Table 34. Global Plasma Derived Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Plasma Derived Medicine Sales Value Share by Region (2027-2032) Table 36. Global Plasma Derived Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Plasma Derived Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Plasma Derived Medicine Sales Value Market Share by Country (2021-2026) Table 39. Global Plasma Derived Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Plasma Derived Medicine Sales Value Market Share by Country (2027-2032) Table 41. Yuanda Shuyang Company Information Table 42. Yuanda Shuyang Business Overview Table 43. Yuanda Shuyang Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Yuanda Shuyang Plasma Derived Medicine Product Portfolio Table 45. Yuanda Shuyang Recent Development Table 46. Takeda Company Information Table 47. Takeda Business Overview Table 48. Takeda Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Takeda Plasma Derived Medicine Product Portfolio Table 50. Takeda Recent Development Table 51. Weiguang Bio Company Information Table 52. Weiguang Bio Business Overview Table 53. Weiguang Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Weiguang Bio Plasma Derived Medicine Product Portfolio Table 55. Weiguang Bio Recent Development Table 56. Tiantan Bio Company Information Table 57. Tiantan Bio Business Overview Table 58. Tiantan Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Tiantan Bio Plasma Derived Medicine Product Portfolio Table 60. Tiantan Bio Recent Development Table 61. CBPO Company Information Table 62. CBPO Business Overview Table 63. CBPO Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. CBPO Plasma Derived Medicine Product Portfolio Table 65. CBPO Recent Development Table 66. Shuanglin Bio Company Information Table 67. Shuanglin Bio Business Overview Table 68. Shuanglin Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Shuanglin Bio Plasma Derived Medicine Product Portfolio Table 70. Shuanglin Bio Recent Development Table 71. RAAS Company Information Table 72. RAAS Business Overview Table 73. RAAS Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. RAAS Plasma Derived Medicine Product Portfolio Table 75. RAAS Recent Development Table 76. Nanyue Bio Company Information Table 77. Nanyue Bio Business Overview Table 78. Nanyue Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Nanyue Bio Plasma Derived Medicine Product Portfolio Table 80. Nanyue Bio Recent Development Table 81. Hualan Bio Company Information Table 82. Hualan Bio Business Overview Table 83. Hualan Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Hualan Bio Plasma Derived Medicine Product Portfolio Table 85. Hualan Bio Recent Development Table 86. Boya Bio Company Information Table 87. Boya Bio Business Overview Table 88. Boya Bio Plasma Derived Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boya Bio Plasma Derived Medicine Product Portfolio Table 90. Boya Bio Recent Development Table 91. Octapharma Company Information Table 92. Octapharma Business Overview Table 93. Octapharma Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Octapharma Plasma Derived Medicine Product Portfolio Table 95. Octapharma Recent Development Table 96. LFB Group Company Information Table 97. LFB Group Business Overview Table 98. LFB Group Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. LFB Group Plasma Derived Medicine Product Portfolio Table 100. LFB Group Recent Development Table 101. KM Biologics Company Information Table 102. KM Biologics Business Overview Table 103. KM Biologics Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. KM Biologics Plasma Derived Medicine Product Portfolio Table 105. KM Biologics Recent Development Table 106. Kedrion Company Information Table 107. Kedrion Business Overview Table 108. Kedrion Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Kedrion Plasma Derived Medicine Product Portfolio Table 110. Kedrion Recent Development Table 111. Grifols Company Information Table 112. Grifols Business Overview Table 113. Grifols Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Grifols Plasma Derived Medicine Product Portfolio Table 115. Grifols Recent Development Table 116. CSL Company Information Table 117. CSL Business Overview Table 118. CSL Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. CSL Plasma Derived Medicine Product Portfolio Table 120. CSL Recent Development Table 121. BPL Company Information Table 122. BPL Business Overview Table 123. BPL Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. BPL Plasma Derived Medicine Product Portfolio Table 125. BPL Recent Development Table 126. Biotest Company Information Table 127. Biotest Business Overview Table 128. Biotest Plasma Derived Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Biotest Plasma Derived Medicine Product Portfolio Table 130. Biotest Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Plasma Derived Medicine Product Image Figure 2. Global Plasma Derived Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma Derived Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Plasma Derived Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Albumin Image Figure 8. Immune Globulin Image Figure 9. Coagulation Factor Image Figure 10. Others Image Figure 11. Global Plasma Derived Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Plasma Derived Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Plasma Derived Medicine Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Pharmacy Image Figure 16. Other Image Figure 17. Global Plasma Derived Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Plasma Derived Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Plasma Derived Medicine Sales Value Share by Application (2021-2032) Figure 20. Global Plasma Derived Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Plasma Derived Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Plasma Derived Medicine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Plasma Derived Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Plasma Derived Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Plasma Derived Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Plasma Derived Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Plasma Derived Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Plasma Derived Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Plasma Derived Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Plasma Derived Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Plasma Derived Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Plasma Derived Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Immune Globulin
  • Coagulation Factor
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Yuanda Shuyang
  • Takeda
  • Weiguang Bio
  • Tiantan Bio
  • CBPO
  • Shuanglin Bio
  • RAAS
  • Nanyue Bio
  • Hualan Bio
  • Boya Bio
  • Octapharma
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Plasma Derived Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Plasma Derived Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Plasma Derived Medicine Market Dynamics
  1. 2.1 Plasma Derived Medicine Industry Trends
  2. 2.2 Plasma Derived Medicine Industry Drivers
  3. 2.3 Plasma Derived Medicine Industry Opportunities and Challenges
  4. 2.4 Plasma Derived Medicine Industry Restraints
3 Plasma Derived Medicine Market by Company
  1. 3.1 Global Plasma Derived Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Plasma Derived Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Plasma Derived Medicine Company Ranking (2024-2026)
  4. 3.4 Global Plasma Derived Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Plasma Derived Medicine Company Product Type and Application
  6. 3.6 Global Plasma Derived Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Plasma Derived Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Plasma Derived Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Plasma Derived Medicine Market by Type
  1. 4.1 Plasma Derived Medicine Type Introduction
  2. 4.1.1 Albumin
  3. 4.1.2 Immune Globulin
  4. 4.1.3 Coagulation Factor
  5. 4.1.4 Others
  6. 4.2 Global Plasma Derived Medicine Sales Value by Type
  7. 4.2.1 Global Plasma Derived Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Plasma Derived Medicine Sales Value by Type (2021-2032)
  9. 4.2.3 Global Plasma Derived Medicine Sales Value Share by Type (2021-2032)
5 Plasma Derived Medicine Market by Application
  1. 5.1 Plasma Derived Medicine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Plasma Derived Medicine Sales Value by Application
  6. 5.2.1 Global Plasma Derived Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Plasma Derived Medicine Sales Value by Application (2021-2032)
  8. 5.2.3 Global Plasma Derived Medicine Sales Value Share by Application (2021-2032)
6 Plasma Derived Medicine Regional Value Analysis
  1. 6.1 Global Plasma Derived Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Plasma Derived Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Plasma Derived Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Plasma Derived Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Plasma Derived Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Plasma Derived Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Plasma Derived Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Plasma Derived Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Plasma Derived Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Plasma Derived Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Plasma Derived Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Plasma Derived Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Plasma Derived Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Plasma Derived Medicine Sales Value Share by Country, 2025 VS 2032
7 Plasma Derived Medicine Country-level Value Analysis
  1. 7.1 Global Plasma Derived Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Plasma Derived Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Plasma Derived Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Plasma Derived Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Plasma Derived Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Plasma Derived Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Plasma Derived Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yuanda Shuyang
  2. 8.1.1 Yuanda Shuyang Company Information
  3. 8.1.2 Yuanda Shuyang Business Overview
  4. 8.1.3 Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
  6. 8.1.5 Yuanda Shuyang Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Plasma Derived Medicine Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Weiguang Bio
  14. 8.3.1 Weiguang Bio Company Information
  15. 8.3.2 Weiguang Bio Business Overview
  16. 8.3.3 Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
  18. 8.3.5 Weiguang Bio Recent Developments
  19. 8.4 Tiantan Bio
  20. 8.4.1 Tiantan Bio Company Information
  21. 8.4.2 Tiantan Bio Business Overview
  22. 8.4.3 Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
  24. 8.4.5 Tiantan Bio Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Plasma Derived Medicine Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Shuanglin Bio
  32. 8.6.1 Shuanglin Bio Company Information
  33. 8.6.2 Shuanglin Bio Business Overview
  34. 8.6.3 Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
  36. 8.6.5 Shuanglin Bio Recent Developments
  37. 8.7 RAAS
  38. 8.7.1 RAAS Company Information
  39. 8.7.2 RAAS Business Overview
  40. 8.7.3 RAAS Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 RAAS Plasma Derived Medicine Product Portfolio
  42. 8.7.5 RAAS Recent Developments
  43. 8.8 Nanyue Bio
  44. 8.8.1 Nanyue Bio Company Information
  45. 8.8.2 Nanyue Bio Business Overview
  46. 8.8.3 Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
  48. 8.8.5 Nanyue Bio Recent Developments
  49. 8.9 Hualan Bio
  50. 8.9.1 Hualan Bio Company Information
  51. 8.9.2 Hualan Bio Business Overview
  52. 8.9.3 Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
  54. 8.9.5 Hualan Bio Recent Developments
  55. 8.10 Boya Bio
  56. 8.10.1 Boya Bio Company Information
  57. 8.10.2 Boya Bio Business Overview
  58. 8.10.3 Boya Bio Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
  60. 8.10.5 Boya Bio Recent Developments
  61. 8.11 Octapharma
  62. 8.11.1 Octapharma Company Information
  63. 8.11.2 Octapharma Business Overview
  64. 8.11.3 Octapharma Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Octapharma Plasma Derived Medicine Product Portfolio
  66. 8.11.5 Octapharma Recent Developments
  67. 8.12 LFB Group
  68. 8.12.1 LFB Group Company Information
  69. 8.12.2 LFB Group Business Overview
  70. 8.12.3 LFB Group Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 LFB Group Plasma Derived Medicine Product Portfolio
  72. 8.12.5 LFB Group Recent Developments
  73. 8.13 KM Biologics
  74. 8.13.1 KM Biologics Company Information
  75. 8.13.2 KM Biologics Business Overview
  76. 8.13.3 KM Biologics Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
  78. 8.13.5 KM Biologics Recent Developments
  79. 8.14 Kedrion
  80. 8.14.1 Kedrion Company Information
  81. 8.14.2 Kedrion Business Overview
  82. 8.14.3 Kedrion Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kedrion Plasma Derived Medicine Product Portfolio
  84. 8.14.5 Kedrion Recent Developments
  85. 8.15 Grifols
  86. 8.15.1 Grifols Company Information
  87. 8.15.2 Grifols Business Overview
  88. 8.15.3 Grifols Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Grifols Plasma Derived Medicine Product Portfolio
  90. 8.15.5 Grifols Recent Developments
  91. 8.16 CSL
  92. 8.16.1 CSL Company Information
  93. 8.16.2 CSL Business Overview
  94. 8.16.3 CSL Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 CSL Plasma Derived Medicine Product Portfolio
  96. 8.16.5 CSL Recent Developments
  97. 8.17 BPL
  98. 8.17.1 BPL Company Information
  99. 8.17.2 BPL Business Overview
  100. 8.17.3 BPL Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 BPL Plasma Derived Medicine Product Portfolio
  102. 8.17.5 BPL Recent Developments
  103. 8.18 Biotest
  104. 8.18.1 Biotest Company Information
  105. 8.18.2 Biotest Business Overview
  106. 8.18.3 Biotest Plasma Derived Medicine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Biotest Plasma Derived Medicine Product Portfolio
  108. 8.18.5 Biotest Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst